The pharma landscape is constantly shifting.
Regulations vary significantly, depending on each country’s economic and medical standards, and each regulatory body has a different process for approving a medicine.
As a result, medicines approved in some countries are not approved in others. However, there is a cross-border solution, and unlicensed medicines (ULMs) could go some way to bridging the healthcare gap for millions of patients around the world.
Check out the rest of the feature here
